US EditionNYS Medical Cannabis Program Reduces Chronic Pain Patients' Reliance on Opioids
A study of 204 adults with chronic pain in New York found a 22% reduction in average daily opioid dose over 18 months linked to pharmacist-supervised medical cannabis use.
- A JAMA Internal Medicine study led by Albert Einstein College of Medicine and Montefiore Health System found participation in New York State Medical Cannabis Program was associated with a 22% reduction in average daily opioid dose.
- Researchers studied adults with chronic pain who were prescribed opioids and newly certified for medical cannabis because chronic pain and opioid addiction are pressing U.S. health challenges, lead author Deepika E. Slawek, M.D., M.S., said.
- Tracking participants for 18 months using the New York State Prescription Monitoring Program, the study found a baseline average of 73.3 mg morphine-equivalent and a 3.5 mg per day difference in months with medical cannabis.
- Julia Arnsten, M.D., M.P.H., said `This research adds to the growing body of evidence supporting a medicalized model of cannabis use, where pharmacists are actively involved in dispensaries and cannabis is treated like other prescription drugs,` and the authors hope it will lead to new policies.
- Supervised medical cannabis dispensing could serve as an important tool in combatting the opioid crisis, and Albert Einstein College of Medicine's capacity, evidenced by more than $192 million in NIH awards in 2024, supports the study's credibility.
28 Articles
28 Articles
NYS Medical Cannabis Program reduces chronic pain patients' reliance on opioids
Adults with chronic pain who participated in New York State's (NYS) Medical Cannabis Program were significantly less likely to require prescription opioids, according to a new study published today in JAMA Internal Medicine and led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
Medical cannabis program reduces opioid use
Adults with chronic pain who participated in New York State's (NYS) Medical Cannabis Program were significantly less likely to require prescription opioids, according to a new study published today in JAMA Internal Medicine and led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
Patients In New York's Medical Marijuana Program Saw 'Significantly Reduced' Opioid Prescriptions, Federally Funded Study Shows
A federally funded study published by the American Medical Association (AMA) is adding more evidence that marijuana can serve as an effective substitute for opioids in chronic pain treatment. The study, published in the Journal of the American Medical Association (JAMA) Internal Medicine on Monday, looked at opioid prescribing trends among chronic pain patients who became involved in the New York’s medical cannabis program between 2018 and 2023.…
LoudounTimes.com
Medical Cannabis Program Reduces Opioid Use
BRONX, N.Y., Dec. 8, 2025 /PRNewswire/ -- Adults with chronic pain who participated in New York State's (NYS) Medical Cannabis Program were significantly less likely to require prescription opioids, according to a new study published today in JAMA Internal Medicine…
*Another* Study Finds Medical Cannabis Reduces Opioid Reliance
A new study suggests participation in New York State’s medical cannabis program was associated with reduced prescription opioid receipts. Chronic pain and opioid addiction remain pressing health issues in the United States — it has been no exaggeration to describe the situation as a crisis. Aside from other various serious impacts of addiction, deaths from […] The post *Another* Study Finds Medical Cannabis Reduces Opioid Reliance appeared first…
Patients In New York’s Medical Marijuana Program Saw ‘Significantly Reduced’ Opioid Prescriptions, Federally Funded Study Shows
A federally funded study published by the American Medical Association (AMA) is adding more evidence that marijuana can serve as an effective substitute for opioids in chronic pain treatment. The study, published in the Journal of the American Medical Association (JAMA) Internal Medicine on Monday, looked at opioid prescribing trends among chronic pain patients who became involved in the New York's medical cannabis program between 2018 and 2023.…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
